Preoperative co-application of bevacizumab and tissue plasminogen activator in vitrectomy for proliferative diabetic retinopathy.

IF 1.1 4区医学 Q3 OPHTHALMOLOGY

Arquivos brasileiros de oftalmologia Pub Date : 2024-03-04 eCollection Date: 2024-01-01 DOI:10.5935/0004-2749.2023-0001

Cengiz Aras, Fevzi Senturk, Sevil Karaman Erdur, Mehmet Selim Kocabora, Mahmut Dogramaci, Cahit Burke, Efe Aras

{"title":"Preoperative co-application of bevacizumab and tissue plasminogen activator in vitrectomy for proliferative diabetic retinopathy.","authors":"Cengiz Aras, Fevzi Senturk, Sevil Karaman Erdur, Mehmet Selim Kocabora, Mahmut Dogramaci, Cahit Burke, Efe Aras","doi":"10.5935/0004-2749.2023-0001","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the clinical benefits of the co-application of bevacizumab and tissue plasminogen activator as adjuncts in the surgical treatment of proliferative diabetic retinopathy.Methods: Patients who underwent vitrectomy for proliferative dia-betic retinopathy complications were preoperatively given in-travitreal injection with either bevacizumab and tissue plasminogen activator (Group 1) or bevacizumab alone (Group 2). Primary outcomes were surgery time and number of intraoperative iatrogenic retinal breaks. Secondary outcomes included changes in the best-corrected visual acuity and postoperative complications at 3 months postoperatively.Results: The mean surgery time in Group 1 (52.95 ± 5.90 min) was significantly shorter than that in Group 2 (79.61 ± 12.63 min) (p<0.001). The mean number of iatrogenic retinal breaks was 0.50 ± 0.59 (0-2) in Group 1 and 2.00 ± 0.83 (0-3) in Group 2 (p<0.001). The best-corrected visual acuity significantly improved in both groups (p<0.001). One eye in each group developed retinal detachment.Conclusion: Preoperative co-application of bevacizumab and tissue plasminogen activator as adjuncts in the surgical treatment of proliferative diabetic retinopathy shortens the surgery time and reduces the number of intraoperative iatrogenic retinal breaks.","PeriodicalId":8397,"journal":{"name":"Arquivos brasileiros de oftalmologia","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos brasileiros de oftalmologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5935/0004-2749.2023-0001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To investigate the clinical benefits of the co-application of bevacizumab and tissue plasminogen activator as adjuncts in the surgical treatment of proliferative diabetic retinopathy.

Methods: Patients who underwent vitrectomy for proliferative dia-betic retinopathy complications were preoperatively given in-travitreal injection with either bevacizumab and tissue plasminogen activator (Group 1) or bevacizumab alone (Group 2). Primary outcomes were surgery time and number of intraoperative iatrogenic retinal breaks. Secondary outcomes included changes in the best-corrected visual acuity and postoperative complications at 3 months postoperatively.

Results: The mean surgery time in Group 1 (52.95 ± 5.90 min) was significantly shorter than that in Group 2 (79.61 ± 12.63 min) (p<0.001). The mean number of iatrogenic retinal breaks was 0.50 ± 0.59 (0-2) in Group 1 and 2.00 ± 0.83 (0-3) in Group 2 (p<0.001). The best-corrected visual acuity significantly improved in both groups (p<0.001). One eye in each group developed retinal detachment.

Conclusion: Preoperative co-application of bevacizumab and tissue plasminogen activator as adjuncts in the surgical treatment of proliferative diabetic retinopathy shortens the surgery time and reduces the number of intraoperative iatrogenic retinal breaks.

查看原文本刊更多论文

在增殖性糖尿病视网膜病变的玻璃体切除术中，术前联合应用贝伐单抗和组织浆肌酶原激活剂。

目的：探讨在增殖性糖尿病视网膜病变的手术治疗中联合应用贝伐单抗和组织纤溶酶原激活剂的临床益处：因增殖性糖尿病视网膜病变并发症而接受玻璃体切除术的患者，术前在玻璃体内注射贝伐单抗和组织纤溶酶原激活剂（第1组）或单独注射贝伐单抗（第2组）。主要结果是手术时间和术中先天性视网膜破损的数量。次要结果包括术后3个月最佳矫正视力和术后并发症的变化：结果：第一组的平均手术时间（52.95±5.90 分钟）明显短于第二组（79.61±12.63 分钟）（p 结论：第一组的平均手术时间（52.95±5.90 分钟）明显短于第二组（79.61±12.63 分钟）：在增殖性糖尿病视网膜病变的手术治疗中，术前联合应用贝伐单抗和组织浆细胞酶原激活剂可缩短手术时间，减少术中视网膜先天性破损的数量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arquivos brasileiros de oftalmologia OPHTHALMOLOGY-

CiteScore

1.60

自引率

0.00%

发文量

200

审稿时长

6-12 weeks

期刊介绍： The ABO-ARQUIVOS BRASILEIROS DE OFTALMOLOGIA (ABO, ISSN 0004-2749 - print and ISSN 1678-2925 - (ABO, ISSN 0004-2749 - print and ISSN 1678-2925 - electronic version), the official bimonthly publication of the Brazilian Council of Ophthalmology (CBO), aims to disseminate scientific studies in Ophthalmology, Visual Science and Health public, by promoting research, improvement and updating of professionals related to the field.